Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).
Latest Information Update: 09 Jul 2024
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Isatuximab (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms IFM2020-05-BENEFIT
- 04 Jun 2024 Results (At data cutoff date ;02 Feb 2024) assessing efficacy and safety of IsaRd vs Isa-VRd in newly diagnosed transplant ineligible multiple myeloma presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 31 May 2024 According to an Adaptive Biotechnologies media release, data from this trial to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31-June 4 in Chicago.
- 13 Dec 2022 Trial design presented at the 64th American Society of Hematology Annual Meeting and Exposition